Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study
Riccardo Candido,Antonio Nicolucci,Monica Larosa,Maria Chiara Rossi,Raffaele Napoli,Enrico Gabellieri,Elena Tortato,Rosa Anna Rabini,Dalia Crazzolara,Luigi Lucibelli,Concetta Aragiusto,Gianluigi Panzolato,Maurizio Di Mauro,Andrea Del Buono,Giuseppe Placentino,Graziano Di Cianni,Gabriele Brandoni,Stefano Fazion,Giovanna Gregori,Antonino Di Benedetto,Carlo De Riva,Annamaria Terracciano,Luciano Zenari,Giuseppe Placentino,Franco Cavalot,Francesca Porcellati,Roberto Anichini,Giuseppe Citro,Paola D'Angelo,Marcello Arca,Lelio Morviducci,Rosa Anna Rabini,Valeria Montani,Luigi Lucibelli,Giuseppe Placentino,Paolo Fiorentini
DOI: https://doi.org/10.1016/j.numecd.2024.03.023
IF: 4.666
2024-05-02
Nutrition Metabolism and Cardiovascular Diseases
Abstract:Background and aims Add-on of basal insulin (BI) to intensify the ongoing therapy with glucagon-like peptide 1 receptor agonist (GLP-1 RA) is recommended, but it is unclear if free or fixed combination of BI and GLP-1 RA produce similar outcomes. A retrospective comparative effectiveness analysis of the add-on of glargine 300 U/mL (Gla-300) to ongoing GLP-1 RA vs. switch to fixed ratio combination of degludec and liraglutide (iDegLira) was performed. Methods and results Real-world data collected in electronic medical records by 32 Italian diabetes clinics. Propensity score (PS) adjustment was applied to assess changes in glycated hemoglobin (HbA1c), fasting blood glucose (FBG), body weight, and BI dose after 6 months from Gla-300 or iDegLira initiation. Compared to iDegLira group (N = 260), Gla-300+GLP-1 RA group (N = 255) had older age and higher levels of HbA1c (9.1 vs. 8.9%). After 6 months, statistically significant greater FBG improvement [estimated mean difference and 95% confidence intervals: −24.05 mg/dl (−37.04; −11.06; p = 0.0003) and BI dose increase [+0.03 U/kg (95%CI 0.00; 0.06); p = 0.009] were found in the free vs. fixed combination group, although low doses of BI (0.2 U/kg) were reached in both groups. Trends of larger HbA1c and body weight reductions with the free combination were also found, without reaching the statistical significance. Conclusion Although inertia in insulin initiation and titration was documented in both groups, higher benefit on FBG control was obtained with free vs. fixed combination, likely due to a better titration of BI and GLP-1 RA.
cardiac & cardiovascular systems,endocrinology & metabolism,nutrition & dietetics